Adalimumab Trough Level
Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of anti TNFα biologics has been a great step forward to ameliorating disease course and keep inflammations at remission levels for prolonged periods of time. Adalimumab is the first anti TNFα biologic on the market approved for patient self-administration by subcutaneous injections. Patients with suboptimal drug concentrations have worse outcomes than those with adequate drug levels. Therapeutic drug monitoring (TDM) for adalimumab has a great potential for the management of anti TNF therapy.
Studies have shown that targeting an adequate adalimumab trough level can support guidance of treatment in IBD patients. An optimal therapeutic window for trough levels seem to be the range from 5 to 12 µg/ml of adalimumab in serum.
Quantum Blue® Adalimumab
The Quantum Blue® Adalimumab assay measures from 1.3 to 35 µg/ml. The target concentrations for the optimal therapeutic window lies well within the linear range of the test. Quantum Blue® Adalimumab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately while following up the patient’s therapy. Quantum Blue® Adalimumab is unique in the diagnostics market, being the only test that can provide fast, reliable TDM for adalimumab and it correlates well with the standard routine ELISAs for adalimumab level determinations.
Quantum Blue® Adalimumab Product Information
||Quantum Blue® Adalimumab
|Time to Result
||15 min (approx.)
|Limit of Detection (LoD)
|| 0.8 µg/ml